Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome

This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study investigates the efficacy and safety of subcutaneous anifrolumab in adult patients with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) who are already receiving standard of care (SOC) treatments. The study enrolled 367 participants aged 18 to 70 years, who were randomized in a 1:1 ratio to receive either anifrolumab or placebo. The primary endpoint is the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response. While the trial is active and not recruiting, specific statistical outcomes such as hazard ratios, odds ratios, relative risks, p-values, or confidence intervals have not yet been reported. Secondary endpoints and safety data, including adverse events, will be crucial to understanding the full clinical implications of anifrolumab in this patient population. The trial is sponsored by AstraZeneca and is expected to complete its primary phase by August 2025.

This study focuses on systemic lupus erythematosus (SLE), a condition where the immune system attacks the body, causing inflammation and pain. Researchers wanted to see if a new treatment, anifrolumab, could help adults with moderate to severe lupus who were not getting better with usual treatments. They compared anifrolumab to a placebo, which is a dummy treatment that looks like the real drug but has no active ingredients. About 360 adults participated in the study, receiving either the new drug or the placebo once a week. The researchers measured how well the patients responded to treatment using a specific assessment tool. While the full results are still pending, the study aims to find out if anifrolumab can help more patients manage their lupus symptoms effectively. If successful, this could offer new hope for those struggling with this challenging condition. However, it’s important to remember that more research is needed to confirm the findings and understand the long-term effects of this treatment.